



CALIPSO-1
TRIAL

JOIN US

In our work to advance the care for people living with autoimmune diseases like lupus, myositis, and scleroderma.



CALiPSO-1 Trial

CALiPSO-1 is a clinical trial designed to test the safety of a new allogeneic, off-the-shelf **cell therapy called CNTY-101** in people with autoimmune diseases. Another purpose is to see if CNTY-101 can reduce inflammation and improve how people with autoimmune diseases feel.



Therapies like **CNTY-101** can potentially overcome many of the challenges of currently available treatment for autoimmunity.

Talk to your doctor to find out if you may be eligible.



CALiPSO-1 Trial

Cell therapy

Cell therapy is an exciting advance for people with autoimmune diseases, offering the potential for remission and/or reducing the need for ongoing medications. **CNTY-101**, an off-the-shelf cell therapy, is manufactured in advance, ensuring consistent, standardized treatment that is readily available for patients when needed. This approach enhances accessibility and reliability with uniform therapeutic effects across all study participants.




WHO IS ELIGIBLE for the CALiPSO-1 Trial

- ✓ 17 years and older
- ✓ Tried at least two medicines, but disease is not under control and/or in remission (scleroderma does not have a definition of remission)



Above 17 years

What to Expect in the **CALiPSO-1** Clinical Trial



FREQUENTLY ASKED QUESTIONS

What are clinical trials?

Clinical trials are research studies that test new medicines in humans with the goal of finding better ways to prevent, diagnose or treat disease. A Phase I clinical trial determines if a new medicine is safe and well-tolerated.

What does cell therapy mean?

Cell therapy is a treatment that involves transplanting healthy cells into a patient, usually to replace or remove damaged cells. Specifically, "chimeric antigen receptor" or CAR therapy has been used to treat types of cancer effectively and are recently being explored to see if they can help patients with certain types of autoimmune diseases. CNTY-101 is a CAR-iNK cell therapy. CAR-iNK, or natural killer cells, recognize and kill B cells, including the B cells that cause autoimmunity.

What are the benefits? What are the possible side effects?

Medicines that target and eliminate B cells have usually been tested first in patients with cancer to see if they are safe and to see how well they work. CNTY-101 has been studied in a trial in patients with cancer. In that study, CNTY-101 was found to be safe, and that the B cells were eliminated as expected, leading to good responses in some cancer patients who had not responded to chemotherapy or CAR T cell therapy.

Since this is a research study, not all of the possible side effects are known. The study doctor will review the possible risks with you during your consent meeting.

Joining a clinical trial can be difficult for patients with busy lives. Century provides the following at **NO COST** to the patient:

- A service for booking and prepaying for hotels and transportation
- Funds for meals for the patient and their caregiver
- Additional stipend for lost wages or childcare can be provided depending on the location and your doctor's practices

Talk to your doctor to find out if you may be eligible.

Contact the study team:
trial_response_century@centurytx.com



www.centurytx.com

Intended for healthcare providers only.